Table 1.
sham | 2 days after BDL | 5 days after BDL | 14 days after BDL | 28 days after BDL | |||||
---|---|---|---|---|---|---|---|---|---|
con | DPO | con | DPO | con | DPO | con | DPO | ||
bilirubin (mmol/l) | 11 ± 0 | 247 ± 33 | 161 ± 17# | 343 ± 26 | 331 ± 30 | 651 ± 42 | 554 ± 58 | 371 ± 44 | 302 ± 41 |
bile infarcts (%) | 0.1 ± 0.1 | 5.7 ± 1.3 | 1.8 ± 0.7# | 3.9 ± 1.2 | 2.3 ± 0.8 | 6.4 ± 0.8 | 2.8 ± 1.0# | 0.7 ± 0.2 | 0.5 ± 0.1 |
mRNA collagen-(I)-α1/GAPDH (rel. density) | 0.15 ± 0.03 | 2.25 ± 0.57 | 0.33 ± 0.08# | 2.65 ± 0.68 | 1.34 ± 0.36 | 5.77 ± 1.54 | 2.02 ± 0.41# | 6.09 ± 2.0 | 3.88 ± 0.66 |
Plasma bilirubin concentration, histologically assessed bile infarcts and hepatic mRNA expression of collagen-(I)-α1 in sham operated mice (n = 3 – 4) and in animals at 2, 5, 14, and 28 days after BDL with administration of either 10 μg/kg body weight darbepoetin-α (DPO) or physiological saline (con) every third day, beginning 24 h after surgery (n = 6 - 10 per group and time point). Data are given as mean ± s.e.
p < 0.05 versus control at the respective time point.
Data are adopted from (Sigal et al. 2010).